Aurinia Reports Third Quarter and Nine Months 2021 Financial Results and Company Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Aurinia Pharmaceuticals (AUPH) Misses Q3 EPS by 6c
November 3, 2021 6:05 AM EDTAurinia Pharmaceuticals (NASDAQ: AUPH) reported Q3 EPS of ($0.39), $0.06 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $14.7 million versus the consensus estimate of $13.88 million.
GUIDANCE:
Aurinia Pharmaceuticals sees FY2021 revenue of $40-50 million, versus the consensus of... More
